Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 229.49% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 08/09/2023 | 229.49% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 05/15/2023 | 229.49% | Chardan Capital | → $20 | Reiterates | Buy → Buy |
| 02/24/2023 | 147.12% | Piper Sandler | → $15 | Initiates Coverage On | → Overweight |
| 02/07/2023 | 229.49% | Chardan Capital | → $20 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月11日 | 229.49% | 查尔丹资本 | →$20 | 重申 | 购买→购买 |
| 08/09/2023 | 229.49% | 查尔丹资本 | →$20 | 重申 | 购买→购买 |
| 2023年05月15日 | 229.49% | 查尔丹资本 | →$20 | 重申 | 购买→购买 |
| 02/24/2023 | 147.12% | 派珀·桑德勒 | →$15 | 开始承保 | →超重 |
| 02/07/2023 | 229.49% | 查尔丹资本 | →$20 | 开始承保 | →购买 |
What is the target price for Orchestra BioMed Hldgs (OBIO)?
乐团BioMed Hldgs(OBIO)的目标价格是多少？
The latest price target for Orchestra BioMed Hldgs (NASDAQ: OBIO) was reported by Chardan Capital on August 11, 2023. The analyst firm set a price target for $20.00 expecting OBIO to rise to within 12 months (a possible 229.49% upside). 5 analyst firms have reported ratings in the last year.
查尔丹资本于2023年8月11日报道了乐团BioMed Hldgs(纳斯达克：OBIO)的最新目标价。这家分析公司将目标价定为20美元，预计OBIO将在12个月内升至(可能上涨229.49%)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Orchestra BioMed Hldgs (OBIO)?
乐团BioMed Hldgs(OBIO)的最新分析师评级是多少？
The latest analyst rating for Orchestra BioMed Hldgs (NASDAQ: OBIO) was provided by Chardan Capital, and Orchestra BioMed Hldgs reiterated their buy rating.
纳斯达克(Sequoia Capital：OBIO)对乐团BioMed Hldgs的最新分析师评级由查尔丹资本提供，乐团BioMed Hldgs重申其买入评级。
When is the next analyst rating going to be posted or updated for Orchestra BioMed Hldgs (OBIO)?
乐团BioMed Hldgs(OBIO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchestra BioMed Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchestra BioMed Hldgs was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公开财务报表，与Orchestra BioMed Hldgs的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。对交响乐团BioMed Hldgs的上一次评级是在2023年8月11日提交的，所以你应该预计下一次评级将在2024年8月11日左右提供。
Is the Analyst Rating Orchestra BioMed Hldgs (OBIO) correct?
分析师对交响乐团BioMed Hldgs(OBIO)的评级正确吗？
While ratings are subjective and will change, the latest Orchestra BioMed Hldgs (OBIO) rating was a reiterated with a price target of $0.00 to $20.00. The current price Orchestra BioMed Hldgs (OBIO) is trading at is $6.07, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的交响乐团BioMed Hldgs(OBIO)评级被重申，目标价在0.00美元至20.00美元之间。目前乐团BioMed Hldgs(OBIO)的交易价格为6.07美元，在分析师的预测范围内。